Article Details
Retrieved on: 2024-09-13 18:12:20
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug Tecentriq (atezolizumab).
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here